Menopausal status modifies breast cancer risk associated with ESR1 PvuII and XbaI polymorphisms in asian women: A HuGE review and meta-analysis

Asian Pacific Journal of Cancer Prevention

Volumn 13, Issue 10, 2012, Pages 5105-5111

  Li, Li Wen ^a   Xu, Lei ^b  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

^b Songjiang District Centre for Disease Prevention and Control   (China)

Author keywords

Breast cancer; Estrogen receptor 1; Meta analysis; Single nucleotide polymorphism

Indexed keywords

EID: 84874009959     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2012.13.10.5105     Document Type: Article

References (34)

1. Baade PD, Youlden DR, Chambers SK (2011). When do I know I am cured? Using conditional estimates to provide better information about cancer survival prospects. Med J Aust, 194, 73-7.
2. Butt Z, Haider SF, Arif S, et al (2012). Breast cancer risk factors: a comparison between pre-menopausal and post-menopausal women. J Pak Med Assoc, 62, 120-4.
3. Cai Q, Shu XO, Jin F, et al (2003). Genetic polymorphisms in the estrogen receptor alpha gene and risk of breast cancer: results from the Shanghai Breast Cancer Study. Cancer Epidemiol Biomarkers Prev, 12, 853-9.
4. Campeau PM, Foulkes WD, Tischkowitz MD (2008). Hereditary breast cancer: new genetic developments, new therapeutic avenues. Hum Genet, 124, 31-42.
5. da Costa BR, Cevallos M, Altman DG, et al (2011). Uses and misuses of the STROBE statement: bibliographic study. BMJ Open, 1, e000048.
6. Deng LL: A study on the relationship between Xba I and PvuII polymorphism of ESR1 gene and breast cancer (2011).
7. Ding SL, Yu JC, Chen ST, et al (2010). Diverse associations between ESR1 polymorphism and breast cancer development and progression. Clin Cancer Res, 16, 3473-84.
8. Einarsdottir K, Darabi H, Li Y, et al (2008). ESR1 and EGF genetic variation in relation to breast cancer risk and survival. Breast Cancer Res, 10, R15.
9. Ferlay J, Shin HR, Bray F, et al (2010). Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer, 127, 2893-917.
10. Higgins JP, Thompson SG (2002). Quantifying heterogeneity in a meta-analysis. Stat Med, 21, 1539-58.
11. Jemal A, Bray F, Center MM, et al (2011). Global cancer statistics. CA Cancer J Clin, 61, 69-90.
12. Jeon S, Choi JY, Lee KM, et al (2010). Combined genetic effect of CDK7 and ESR1 polymorphisms on breast cancer. Breast Cancer Res Treat, 121, 737-42.
13. Key T, Appleby P, Barnes I, et al (2002). Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. J Natl Cancer Inst, 94, 606-16.
14. Laudanski P, Koda M, Kozlowski L, et al (2004). Expression of glucose transporter GLUT-1 and estrogen receptors ER-alpha and ER-beta in human breast cancer. Neoplasma, 51, 164-8.
15. Li N, Dong J, Hu Z, et al (2010). Potentially functional polymorphisms in ESR1 and breast cancer risk: a meta-analysis. Breast Cancer Res Treat, 121, 177-84.
16. Li Y, Ambrosone CB, McCullough MJ, et al (2009). Oxidative stress-related genotypes, fruit and vegetable consumption and breast cancer risk. Carcinogenesis, 30, 777-84.
17. Lu X, Li B, Wei JM, et al (2005). The XbaIsand PvuIIgene polymorphiams of the estrogen receptor αgene in Chinese women with breast cancer. Chin J Surg, 43, 21-4.
18. McCormack VA, Boffetta P (2011). Today's lifestyles, tomorrow's cancers: trends in lifestyle risk factors for cancer in low- and middle-income countries. Ann Oncol, 22, 2349-57.
19. Pabalan N, Jarjanazi H, Sung L, et al (2012). Menopausal status modifies breast cancer risk associated with the myeloperoxidase (MPO) G463A polymorphism in Caucasian women: a meta-analysis. PLoS One, 7, e32389.
20. Parker MG, Cowley SM, Heery D, et al (1997). Function of estrogen receptors in breast cancer. Breast Cancer, 4, 204-8.
21. Peters JL, Sutton AJ, Jones DR, et al (2006). Comparison of two methods to detect publication bias in meta-analysis. JAMA, 295, 676-80.
22. Sakoda LC, Blackston CR, Doherty JA, et al (2011). Selected estrogen receptor 1 and androgen receptor gene polymorphisms in relation to risk of breast cancer and fibrocystic breast conditions among Chinese women. Cancer Epidemiol, 35, 48-55.
23. Shen Y, Li DK, Wu J, et al (2006). Joint effects of the CYP1A1 MspI, ERalpha PvuII, and ERalpha XbaI polymorphisms on the risk of breast cancer: results from a population-based case-control study in Shanghai, China. Cancer Epidemiol Biomarkers Prev, 15, 342-7.
24. Shin A, Kang D, Nishio H, et al (2003). Estrogen receptor alpha gene polymorphisms and breast cancer risk. Breast Cancer Res Treat, 80, 127-31.
25. Sobti RC, Askari M, Nikbakht M, et al (2012). Genetic variants of EGFR (142285G>A) and ESR1 (2014G>A) gene polymorphisms and risk of breast cancer. Mol Cell Biochem, 369, 217-25.
26. Song CG, Hu Z, Yuan WT, et al (2006). Er-α gene polymorphism and the risk of non-BRCA1/2 hereditary breast cancer. Chin J Gen Surg, 21, 637-40.
27. Stuckey A (2011). Breast cancer: epidemiology and risk factors. Clin Obstet Gynecol, 54, 96-102.
28. Surekha D, Vishnupriya S, Rao DN, et al (2007). PvuII polymorphism of estrogen receptor-alpha gene in breast cancer. Indian J Hum Genet, 13, 97-101.
29. Tsezou A, Tzetis M, Gennatas C, et al (2008). Association of repeat polymorphisms in the estrogen receptors alpha, beta (ESR1, ESR2) and androgen receptor (AR) genes with the occurrence of breast cancer. Breast, 17, 159-66.
30. Weiderpass E, Persson I, Melhus H, et al (2000). Estrogen receptor alpha gene polymorphisms and endometrial cancer risk. Carcinogenesis, 21, 623-7.
31. Zhang FC, Xu YC, Lin YM (2004). Association between ESR1 and breast cancer. Conference article.
32. Zhang L, Liu JL, Zhang YJ, et al (2011) Association between HLA-B*27 polymorphisms and ankylosing spondylitis in Han populations: a meta-analysis. Clin Exp Rheumatol, 29, 285-92.
33. Zhang W, Yu YY (2007). Polymorphisms of short tandem repeat of genes and breast cancer susceptibility. Eur J Surg Oncol, 33, 529-34.
34. Zintzaras E, Ioannidis JP (2005). Heterogeneity testing in meta-analysis of genome searches. Genet Epidemiol, 28, 123-37.